How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia?

van Breemen, Richard B

How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia? [electronic resource] - The Journal of nutrition Aug 2005 - 2062S-4S p. digital

Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

0022-3166

10.1093/jn/135.8.2062S doi


Anticarcinogenic Agents--therapeutic use
Biomarkers--blood
Carotenoids--therapeutic use
Humans
Lycopene
Male
Placebos
Prostate-Specific Antigen--blood
Prostatic Hyperplasia--blood
Prostatic Neoplasms--pathology
Reproducibility of Results